The newest concept for treating coronary artery disease is to induce hearts to grow their own new blood vessels to bypass damaged tissue or clogged arteries. Unfortunately, clinical trials of two important blood-vessel growth factors -- fibroblast growth factor 2 (FGF2) and vascular endothelial growth factor (VEGF) -- have not produced stellar results.
